开发一种二基诺林-皮拉林GluN2C/2D-选择性负基调节器的N-甲基-d-酸盐受体
Michael P D'Erasmo1, Nicholas S Akins1, Peipei Ma1
1Department of Chemistry, Emory University, Atlanta, Georgia 30322, United States.
ACS chemical neuroscience
|August 11, 2023
概括
研究人员开发了一种新化合物, (S) -(-) -2i (DQP-997-74),可选择性抑制特定的N-甲基-D-酸盐受体 (NMDARs),这些受体与神经系统疾病有关. 这种改进的化合物在临床前模型中显示出高选择性和有效性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 对N-甲基-D-酸盐受体 (NMDARs) 的选择性抑制是神经系统疾病 (如和阿尔茨海默病) 的关键治疗策略.
- 之前的NMDAR抑制剂,如二基诺林-皮拉 (DQP) 类似物2a (DQP-26),表现出有限的亚单元选择性和差的药用动力学特性,阻碍了体内应用.
研究的目的:
- 为了提高DQP类似物对NMDAR抑制的选择性和药理动力学特征.
- 为了确定新型的NMDAR调节剂,提高功效和大脑透,用于神经疾病的潜在治疗用途.
主要方法:
- 结构-活性关系研究在DQP类型的酸盐侧链上进行.
- 研究了前药物策略,以掩盖碳酸组并改善细胞膜的透性.
- 针对各种NMDAR子单元和其他受体 (AMPA, kainate, GluN1/GluN3) 评估了新型类似物的选择性和功效.
主要成果:
- 发现了类似的 (S) - ((-) - 2i (DQP-997-74),对含有GluN2C/D的NMDAR具有超过100倍和300倍的选择性,而不是含有GluN2A/B的NMDAR.
- 与之前的类型 (S) - 2a相比,化合物 (S) - 2i显示出功效增加了5倍,并显示了GluN2C/D NMDARs的时间依赖抑制.
- 在结硬化综合体 (TSC) 诱导的的小鼠模型中,2i化合物显著降低了发作事件,与GluN2C子单元的上调相关.
结论:
- 化合物 (S) -(-)-2i是一种强效和选择性的GluN2C/D NMDAR抑制剂,具有改善的药理动力学特性,使其成为目标验证的有价值工具.
- 改进的大脑透的乙化类似物表明一个有前途的治疗策略NMDAR相关的神经障碍.
- 选择性NMDAR调制具有显著的治疗潜力,用于异常刺激性神经传递特征的疾病.
更多相关视频
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
13.7K
10:29Multi-photon Intracellular Sodium Imaging Combined with UV-mediated Focal Uncaging of Glutamate in CA1 Pyramidal Neurons
Published on: October 8, 2014
14.1K
相关概念视频
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.3K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
606
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
606
Ligand-gated Ion Channels
12.5K
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
12.5K
GPCR Desensitization
6.1K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.1K
